BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1165 related articles for article (PubMed ID: 26809192)

  • 1. Xanthotoxin prevents bone loss in ovariectomized mice through the inhibition of RANKL-induced osteoclastogenesis.
    Dou C; Chen Y; Ding N; Li N; Jiang H; Zhao C; Kang F; Cao Z; Quan H; Luo F; Xu J; Dong S
    Osteoporos Int; 2016 Jul; 27(7):2335-2344. PubMed ID: 26809192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cordycepin Prevents Bone Loss through Inhibiting Osteoclastogenesis by Scavenging ROS Generation.
    Dou C; Cao Z; Ding N; Hou T; Luo F; Kang F; Yang X; Jiang H; Xie Z; Hu M; Xu J; Dong S
    Nutrients; 2016 Apr; 8(4):231. PubMed ID: 27104563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The naturally derived small compound Osthole inhibits osteoclastogenesis to prevent ovariectomy-induced bone loss in mice.
    Zhao D; Wang Q; Zhao Y; Zhang H; Sha N; Tang D; Liu S; Lu S; Shi Q; Zhang Y; Dong Y; Wang Y; Shu B
    Menopause; 2018 Dec; 25(12):1459-1469. PubMed ID: 29944638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel RANKL-targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen species.
    Hong G; Chen Z; Han X; Zhou L; Pang F; Wu R; Shen Y; He X; Hong Z; Li Z; He W; Wei Q
    Clin Transl Med; 2021 May; 11(5):e392. PubMed ID: 34047464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kirenol inhibits RANKL-induced osteoclastogenesis and prevents ovariectomized-induced osteoporosis via suppressing the Ca
    Zou B; Zheng J; Deng W; Tan Y; Jie L; Qu Y; Yang Q; Ke M; Ding Z; Chen Y; Yu Q; Li X
    Phytomedicine; 2021 Jan; 80():153377. PubMed ID: 33126167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities.
    Liu Y; Wang C; Wang G; Sun Y; Deng Z; Chen L; Chen K; Tickner J; Kenny J; Song D; Zhang Q; Wang H; Chen Z; Zhou C; He W; Xu J
    Theranostics; 2019; 9(16):4648-4662. PubMed ID: 31367247
    [No Abstract]   [Full Text] [Related]  

  • 8. Dauricine attenuates ovariectomized-induced bone loss and RANKL-induced osteoclastogenesis via inhibiting ROS-mediated NF-κB and NFATc1 activity.
    Lin X; Yuan G; Yang B; Xie C; Zhou Z; Liu Y; Liu Z; Wu Z; Akimoto Y; Li N; Xu R; Song F
    Phytomedicine; 2024 Jul; 129():155559. PubMed ID: 38579642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseurotin A Inhibits Osteoclastogenesis and Prevents Ovariectomized-Induced Bone Loss by Suppressing Reactive Oxygen Species.
    Chen K; Qiu P; Yuan Y; Zheng L; He J; Wang C; Guo Q; Kenny J; Liu Q; Zhao J; Chen J; Tickner J; Fan S; Lin X; Xu J
    Theranostics; 2019; 9(6):1634-1650. PubMed ID: 31037128
    [No Abstract]   [Full Text] [Related]  

  • 10. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
    Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
    J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hederagenin protects mice against ovariectomy-induced bone loss by inhibiting RANKL-induced osteoclastogenesis and bone resorption.
    Tian K; Su Y; Ding J; Wang D; Zhan Y; Li Y; Liang J; Lin X; Song F; Wang Z; Xu J; Liu Q; Zhao J
    Life Sci; 2020 Mar; 244():117336. PubMed ID: 31972206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herbacetin inhibits RANKL-mediated osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Li L; Sapkota M; Kim SW; Soh Y
    Eur J Pharmacol; 2016 Apr; 777():17-25. PubMed ID: 26923730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vinpocetine inhibits RANKL-induced osteoclastogenesis and attenuates ovariectomy-induced bone loss.
    Zhu M; Liu H; Sun K; Liu J; Mou Y; Qi D; Zhou C; Abudunaibi M; Tasiken B; Li J; Cheng H; Huang H
    Biomed Pharmacother; 2020 Mar; 123():109769. PubMed ID: 31846839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Picrasidine I from Picrasma Quassioides Suppresses Osteoclastogenesis via Inhibition of RANKL Induced Signaling Pathways and Attenuation of ROS Production.
    Kong L; Wang B; Yang X; Guo H; Zhang K; Zhu Z; Liu J; Hao D
    Cell Physiol Biochem; 2017; 43(4):1425-1435. PubMed ID: 29017159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GSH attenuates RANKL-induced osteoclast formation in vitro and LPS-induced bone loss in vivo.
    Han B; Geng H; Liu L; Wu Z; Wang Y
    Biomed Pharmacother; 2020 Aug; 128():110305. PubMed ID: 32485573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
    Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
    Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-Linolenic Acid Inhibits Receptor Activator of NF-κB Ligand Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) Signaling Pathways.
    Song J; Jing Z; Hu W; Yu J; Cui X
    Med Sci Monit; 2017 Oct; 23():5056-5069. PubMed ID: 29061958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of osteoclast differentiation and bone resorption by sauchinone.
    Han KY; Yang D; Chang EJ; Lee Y; Huang H; Sung SH; Lee ZH; Kim YC; Kim HH
    Biochem Pharmacol; 2007 Sep; 74(6):911-23. PubMed ID: 17662251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.